Finbold 2025-08-13 09:07:08

Palantir co-founder Peter Thiel buys into crypto firm as stock soars 250%

Shares of 180 Life Sciences Corp. (NASDAQ: ATNF ) surged 206.59% on Tuesday to close at $10.24, after regulatory filings revealed that billionaire tech investor Peter Thiel had acquired a 7.5% stake in the company. The momentum carried into pre-market trading Wednesday, with the stock climbing another 56.05% to $15.98. ATNF pre-market stock price. Source: Google Finance According to a Schedule 13G filing with the U.S. Securities and Exchange Commission, Thiel holds 11,592,241 shares in 180 Life Sciences, representing shared voting and dispositive power over the entire stake, with the filing confirming this position amounts to 7.5% of the company’s outstanding shares. What is 180 Life Sciences? 180 Life Sciences, a clinical-stage biotech focused on inflammatory diseases, also disclosed that it holds 82,186 ETH on its balance sheet, currently valued at approximately $349 million based on Ethereum’s price of $4,600 at the time of publication. Ethereum adds a unique dimension to the company’s assets, providing potential liquidity and diversification benefits. The convergence of high-profile investor backing, significant digital asset holdings, and renewed market interest has catapulted ATNF into the spotlight, with traders closely watching for the next catalyst that could drive further gains. The post Palantir co-founder Peter Thiel buys into crypto firm as stock soars 250% appeared first on Finbold .

Most Read News

AguilaTrades Loss: Shocking $1.85 Million Wip...
2025-08-14
Spot the 4 Top New Meme Coins to Invest in No...
2025-08-14
Someone counter-hacked a North Korean IT work...
2025-08-14
Greenidge Bitcoin Mining Soars: A Stellar 110...
2025-08-14
Crucial: Bain Capital Ventures COMP Sale Loom...
2025-08-14
BlockchainFX & Ozak AI Presales Raise Million...
2025-08-14
Solana Eyes $250 Breakout as ETH Holds $4,600...
2025-08-14
Can JASMY sustain its 27% weekly rally? – THE...
2025-08-14

Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.